<DOC>
	<DOC>NCT02937675</DOC>
	<brief_summary>This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of eFT508. The study will evaluate oral daily administration of eFT508. Treatment and study subject evaluation will be performed in 21-day cycles.</brief_summary>
	<brief_title>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies</brief_title>
	<detailed_description />
	<criteria>1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 2. Presence of an active hematological malignancy. 3. Presence of measurable disease. 4. Hematological malignancy has been previously treated, has relapsed after or progressed during prior therapy, and has limited potential for benefit from currently available therapy including hematopoietic stem cell transplantation. 5. At least 2 weeks post any treatments/therapies at the time of first dose. 6. Adequate bone marrow function. 7. Adequate hepatic function. 8. Adequate renal function. 9. Normal coagulation panel. 10. Negative antiviral serology. 11. Willingness to use effective contraception. 1. Central nervous system malignancy 2. Gastrointestinal disease 3. Significant cardiovascular disease 4. Significant ECG abnormalities. 5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or requirement for systemic anticoagulation 6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) 7. Pregnancy or breastfeeding. 8. Major surgery within 4 weeks before the start of study therapy. 9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids 10. Use of drugs that could prolong the QT interval within 7 days before the start of study therapy. 11. Use of drugs that might pose a risk of a drugdrug interaction within 27 days before the start of study therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>small molecule inhibitor of protein translation</keyword>
	<keyword>immunomodulator</keyword>
	<keyword>phase 1 dose escalation</keyword>
</DOC>